title: National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer disease trial methodology.
abstract: The authors describe the development of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) protocol for Alzheimer disease (AD), a trial developed in collaboration with the National Institute of Mental Health (NIMH), assessing the effectiveness of atypical antipsychotics for psychosis and agitation occurring in AD outpatients. They provide an overview of the methodology utilized in the trial as well as the clinical-outcomes and effectiveness measures that were implemented.
authors.affiliation: Clinical Antipsychotic Trials of Intervention Effectiveness Program of the National Institute of Mental Health at the University of North Carolina, Chapel Hill, NC, USA. lschneid@usc.edu
authors.forename: L S
authors.initials: LS
authors.lastname: Schneider
authors.forename: P N
authors.initials: PN
authors.lastname: Tariot
authors.forename: C G
authors.initials: CG
authors.lastname: Lyketsos
authors.forename: K S
authors.initials: KS
authors.lastname: Dagerman
authors.forename: K L
authors.initials: KL
authors.lastname: Davis
authors.forename: S
authors.initials: S
authors.lastname: Davis
authors.forename: J K
authors.initials: JK
authors.lastname: Hsiao
authors.forename: D V
authors.initials: DV
authors.lastname: Jeste
authors.forename: I R
authors.initials: IR
authors.lastname: Katz
authors.forename: J T
authors.initials: JT
authors.lastname: Olin
authors.forename: B G
authors.initials: BG
authors.lastname: Pollock
authors.forename: P V
authors.initials: PV
authors.lastname: Rabins
authors.forename: R A
authors.initials: RA
authors.lastname: Rosenheck
authors.forename: G W
authors.initials: GW
authors.lastname: Small
authors.forename: B
authors.initials: B
authors.lastname: Lebowitz
authors.forename: J A
authors.initials: JA
authors.lastname: Lieberman
mesh_terms: D000368:Aged; D000465:Algorithms; D000544:Alzheimer Disease / Q000191:economics / Q000523:psychology*; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use*; D001569:Benzodiazepines; D015283:Citalopram / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D006801:Humans; D000077152:Olanzapine; D010349:Patient Compliance; D010890:Pirenzepine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000191:economics / Q000627:therapeutic use*; D011595:Psychomotor Agitation / Q000188:drug therapy* / Q000191:economics / Q000209:etiology*; D011618:Psychotic Disorders / Q000188:drug therapy* / Q000191:economics / Q000209:etiology*; D018967:Risperidone / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D014150:Antipsychotic Agents; D015283:Citalopram; D001569:Benzodiazepines; D010890:Pirenzepine; D018967:Risperidone; D000077152:Olanzapine